Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
White Paper - January 10, 2011 - pdf
By: Michael Arlotto, Ph.D
Select one of the options below to save this article to your library.
The biopharmaceutical industry is at a critical point of considerable change. Faced with mounting pressure to move drug candidates through the development cycle more quickly, companies are also trying to navigate the substantial risk involved in pursuing a growing portfolio of products – and the current paradigm is clearly not tenable. To successfully increase shareholder value, mitigate risk, and improve clinical execution, biopharmaceutical companies must explore alliances that meet the needs of the New Health and produce medicines that speak to the needs of the entire constellation of stakeholders. By bringing more, non-traditional parties into strategic alliances with an eye toward reimbursement realities, the industry will accelerate innovation, experience a healthier return on investment, and provide better patient outcomes – thus securing its vital role in the global healthcare ecosystem.
This paper explores the reasons for a new partnership model and offers suggestions for how to construct an alliance appropriate for the New Health.
Michael Arlotto, Ph.D., is Senior Vice President of Corporate Development with Quintiles, a role in which he applies his expertise in finding innovative solutions for biopharmaceutical companies to bring new products to market faster and maximize product sales. Early on in his career with Quintiles, Dr. Arlotto handled projects for all North American Clinical Development Services, managing a staff of about 250 research professionals in multiple locations in the United States and Canada.
Prior to joining Quintiles in 1997, Dr. Arlotto implemented an in vitro metabolism laboratory, creating a liver microsomal library and developing liver-slice methodology for Bayer Corp. As Director of Scientific Planning and Development for Dallas Biomedical, he directed research projects in oncology, immunology, biochemistry and molecular biology. Previously, as a research scientist, he worked on the application of recombinant enzymes for in vitro drug metabolism and toxicology testing, among other projects.
Dr. Arlotto received a bachelor’s degree in toxicology from the Philadelphia College of Pharmacy and Science before earning a doctorate in toxicology from Kansas University Medical Center. He completed a postdoctoral fellowship at Oak Ridge Associated Universities’ National Center for Toxicology Research in Arkansas. Over the years, he has acquired additional executive and applied science training through numerous short courses at universities and technology centers around the country. Dr. Arlotto has published dozens of abstracts and articles in research journals and has patented a generation of radioactive oxidation products.